Customized Pharmacokinetics Studies with Knockout Rat Models
News Jul 03, 2012
NoAb BioDiscoveries, in collaboration with SAGE Labs, is introducing the use of SAGE™ knockout rats with its tools to investigate the Blood Brain Barrier including micro dialysis and serial CSF collection, as a service to drug discovery researchers.
Rats provided by SAGE (Sigma Advanced Genetic Engineering) Labs are available with knockouts of the specific drug transporter genes Mdr1a, Mrp1, Mrp2, Bcrp, or Oct1.
These advanced animal models are designed to study and characterize the drug-like properties of compounds in vivo.
Dan Lichtman, President and CEO of NoAb BioDiscoveries, said “This partnership with SAGE Labs strengthens our service offering in drug discovery research. Preclinical researchers will benefit from the combined expertise and leadership of NoAb and SAGE.”
NoAb BioDiscoveries is a preclinical Contract Research Organization that offers a wide range ADME-PK Discovery services, specializing in in vivo models, in vitro assays and bioanalytical support.
In addition to standard drug disposition studies, specific surgical catheterization points available at NoAb BioDiscoveries include Jugular Vein, Carotid Artery, Hepatoportal Vein, Bile Duct, and Intestinal Subsections.
Such customized models form an important component of the tools that an investigator can use to address unique and specific questions about their compounds.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018